Peptide Half-Life: What the Number Means and Why Sources Disagree

Elimination half-life is the time it takes for the concentration of a compound in the blood to fall by half once absorption is over. It is the single pharmacokinetic number most often quoted for peptides, and it explains why some are studied several times a day and others once a week. It is also quoted inconsistently, because the same name can cover different molecules, routes and measurements.

Elimination, terminal and effective half-life

• Elimination half-life describes how fast the body clears a compound: liver and kidney clearance, enzymatic breakdown in the blood, uptake into tissues. After one half-life, half is left; after two, a quarter; after five, about 3%.

• Terminal half-life is the slope of the last, slowest phase of the concentration curve. Many drugs fall quickly at first (distribution into tissues) and then slowly (true elimination). Labels usually report the terminal value. For a long-acting injection it can also reflect slow release from the injection site rather than elimination: the curve cannot fall faster than the drug leaves the depot.

• Effective half-life is the one that describes accumulation with repeated doses: how much builds up between doses at steady state. It can differ from the terminal value when a compound has more than one phase.

None of these is the same as how long an effect lasts. A peptide can be cleared and still leave downstream changes; receptor-level effects can outlast the molecule, or fade while it is still present.

Why formulation and route change the number

Half-life belongs to a molecule in a specific form, given a specific way:

1. Chemical modification. Fatty-acid acylation lets semaglutide and tirzepatide bind albumin, which shields them from breakdown and from kidney filtration; PEGylation and the drug affinity complex (DAC) on CJC-1295 do something similar. Native GLP-1 lasts minutes; semaglutide about a week (Kontermann 2016; Lau and Dunn 2018).

2. Route. Intravenous gives the clearance of the molecule itself. Subcutaneous adds absorption from the injection site, which can dominate the curve. Oral and intranasal routes add absorption and first-pass losses, and often very low bioavailability.

3. Free versus bound. For compounds that circulate bound to carrier proteins (IGF-1 is the clearest case), the free and total half-lives differ enormously.

4. Species. Rodent clearance is generally faster; a figure from a mouse study does not transfer to people.

Reported half-lives across commonly discussed compounds

The half-life column of the peptide dosage chart lists the value recorded on every profile, and each profile cites its source.

What half-life determines

Time to steady state

With repeated administration at a fixed interval, levels approach a plateau after about four to five half-lives. For a compound with a seven-day half-life given weekly, that is roughly a month, which is why a change in a weekly incretin's schedule takes weeks to show fully in blood levels.

Accumulation

The longer the half-life relative to the interval between doses, the more each dose adds to what is left of the last one. A compound with a half-life of minutes does not accumulate between daily doses; a compound with a weekly half-life given weekly does.

Washout

The same arithmetic runs in reverse: about four to five half-lives after the last dose, a compound is largely cleared. That is hours for a short peptide and more than a month for semaglutide, which is why labels give long washout periods before, for example, a planned pregnancy.

Why quoted figures disagree

1. Different molecules, same name. CJC-1295 is the clearest case; TB-500 versus thymosin beta-4 is another.

2. Different routes and formulations. An intravenous study and a subcutaneous study of one molecule can both be correct.

3. Terminal versus effective values. A paper may report the terminal phase, another the effective half-life.

4. Different species. Animal values are often quoted as if they were human.

5. Not measured at all. For most research peptides, no human pharmacokinetic study exists, and numbers circulating online are estimates or borrowed from a related molecule. A profile that says "not characterized" is giving the accurate answer.

Clinical evidence considerations

Half-life tells you about exposure, not about benefit or safety. A compound can be cleared slowly and do nothing useful, or quickly and have a lasting effect. For approved medicines, the label's schedule comes from trials that tested specific doses and intervals, not from half-life arithmetic alone; for investigational compounds, see each trial's design, such as the retatrutide clinical trials.

Frequently asked questions

What is the half-life of a peptide?

The time for its blood concentration to fall by half after absorption. It ranges from a few minutes for native peptide hormones to about a week for modified GLP-1 drugs such as semaglutide.

What is the difference between terminal and effective half-life?

Terminal half-life is the slope of the last, slowest phase of the concentration curve. Effective half-life describes how much a compound accumulates with repeated dosing. They match for simple one-phase drugs and differ for multi-phase ones.

How long until a weekly drug reaches steady state?

About four to five half-lives: roughly a month for a compound with a seven-day half-life given once a week.

Does half-life tell you how long an effect lasts?

Not directly. It describes clearance of the compound. Effects can outlast it, and receptor-level changes can persist longer still.